The International Coalition of Medicines Regulatory Authorities, an executive-level coalition of regulators from 29 medicines regulatory authorities from territories including Australia, Brazil, Canada, China, the European Union, and the United States, among others, recently released a statement of confidence in biosimilars.
The International Coalition of Medicines Regulatory Authorities (ICMRA), an executive-level coalition of regulators from 29 medicines regulatory authorities from territories including Australia, Brazil, Canada, China, the European Union, and the United States, among others, recently released a statement of confidence in biosimilars.
In the statement aimed at educating healthcare professionals, ICMRA said that it aims to provide assurance for stakeholders on the robust regulatory process for approval and monitoring of biosimilars and to highlight the benefits that biosimilars can provide for both patients and healthcare systems at large.
Biosimilars are medicines with proven quality, manufactured to the same quality standards as other biologics, and are only approved after rigorous scientific evaluation.
They explain that biosimilars must demonstrate high similarity to their reference products and that the foundation for providing this evidence of similarity comprises the extensive comparability studies that are undertaken using state-of-the-art analytical techniques that allow for robust comparison of the products’ molecules. Full clinical programs are not necessary except to help address remaining questions that may require human data (such as pharmacokinetics) to evaluate.
ICMRA highlights the fact that biosimilars have been used safely for many years, and no relevant differences in adverse effects have been observed between biosimilars and their references.
While regulatory pathways differ across countries, and while substitution at the pharmacy level is an issue regulated by nations individually, global regulators have confidence in the rigor of the approval process for biosimilars, and many regulators—and providers—accept switching to biosimilars as part of clinical practice.
However, ICMRA notes, copy biologics—sometimes called biomimics or biocopies—that are not approved on the basis of a robust biosimilar regulatory pathway must not be considered biosimilars; these noncomparable products have not been assessed in extensive comparability studies, so their quality is not assured.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.